CRL 195.77 (+0.81%)
US1598641074Medical Diagnostics & ResearchDiagnostics & Research

Charles River Laboratories (CRL) Competitor Comparison

We are evaluating the key criteria listed to compare Charles River Laboratories (CRL) against its competitors in the Diagnostics & Research industry.

EBITDA - CRL ranking 12 / 56

These are the competitors of Charles River Laboratories in the industry Diagnostics & Research ranked by ebitda
1. Thermo Fisher Scientific TMO
10.84B
2. Danaher DHR
9.27B
3. IQVIA Holdings IQV
2.72B
4. Laboratory Corp of America Holdings LH
2.13B
5. Quest Diagnostics DGX
1.7B
6. Agilent Technologies A
1.68B
7. Icon ICLR
1.56B
8. PerkinElmer PKI
1.29B
9. Mettler-Toledo MTD
1.24B
10. IDEXX Laboratories IDXX
1.19B
11. Waters WAT
989.37M
12. Charles River Laboratories CRL
972.45M
13. DexCom DXCM
659.6M
14. Syneos Health SYNH
587.48M
15. Qiagen QGEN
534.58M
16. Sotera Health SHC
450.6M
17. Ortho Clinical Diagnostics Holdings OCDX
450.5M
18. Medpace Holdings MEDP
351.19M
19. Illumina ILMN
317M
20. Neogen NEOG
248.24M
21. Lantheus Holdings LNTH
240.89M
22. RadNet RDNT
215.84M
23. Global Cord Blood CO
91.38M
24. Bioventus BVS
47.99M
25. National Research NRC
46.45M
26. Inotiv NOTV
45.48M
27. Interpace Biosciences IDXG
2.94M
28. Psychemedics PMD
-2.63M
29. SeqLL SQL
-5.24M
30. bioAffinity Technologies BIAF
-7.18M
31. Precipio PRPO
-7.77M
32. Heska HSKA
-9.32M
33. Trinity Biotech TRIB
-14.77M
34. Organovo Holdings ONVO
-19.12M
35. Aspira Womens Health AWH
-19.58M
36. MDxHealth MDXH
-21.56M
37. Olink Holding OLK
-22.65M
38. Enzo Biochem ENZ
-23.43M
39. Exagen XGN
-24.49M
40. Neuronetics STIM
-31.15M
41. Fulgent Genetics FLGT
-37.6M
42. NeoGenomics NEO
-38.06M
43. Sera Prognostics SERA
-40M
44. Co-Diagnostics CODX
-40.4M
45. MaxCyte MXCT
-42.96M
46. Biodesix BDSX
-45.09M
47. DarioHealth DRIO
-46.07M
48. Prenetics Global PRE
-62.62M
49. CareDx CDNA
-84.34M
50. Personalis PSNL
-95.1M
51. Myriad Genetics MYGN
-99.7M
52. Exact Sciences EXAS
-144.16M
53. Twist Bioscience TWST
-181.06M
54. Pacific Biosciences of California PACB
-290.1M
55. Guardant Health GH
-476.22M
56. Natera NTRA
-482.57M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.